| 词条 | Narnatumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458283354 | type = mab | image = | alt = | mab_type = mab | source = o | target = MST1R (aka RON) | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1188275-92-4 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | KEGG = D10074 | C=6454 | H=10026 | N=1754 | O=2020 | S=44 | molecular_weight = 145.9 kg/mol |drug_name=|caption=|licence_EU=|licence_US=}}Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2] Narnatumab was developed by ImClone Systems. References1. ^{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf}} {{monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^{{cite web|title=Narnatumumab|url=http://adisinsight.springer.com/drugs/800032136|website=AdisInsight|accessdate=31 January 2017}} 2 : Monoclonal antibodies|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。